YD Bio Ltd (YDES) stock forecast & analysis
4.74
NasdaqGM · USD
Down: -0.03, -0.6%
1 analysis
- Open
- 4.77
- Previous close
- 4.77
- Day range
- 4.67 – 4.88
- 52-week range
- 1.70 – 22.00
- Volume (shares)
- 51.60K
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 70.83M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- Not available
- Market cap
- 335.74M
Market Scanner’s AI analysis of YD Bio Ltd (YDES), updated September 2026: YD Bio Ltd's recent analyses covered significant revenue growth and product launches, alongside mixed profitability trends and technical indicators.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of YD Bio Ltd (YDES) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
YD Bio Ltd's recent analyses covered significant revenue growth and product launches, alongside mixed profitability trends and technical indicators.
Recent analyses for YD Bio Ltd (YDES) examined its substantial year-over-year quarterly revenue growth and recent product launches in Taiwan and Canada. The reports also noted the company's strong cash position and current ratios, contrasted with historical net losses in prior years. Technical indicators showed short-term upward momentum with mixed signals on longer-term trends.
YDES news & sentiment
News reports highlighted YD Bio Ltd's active engagement in research, product launches, and strategic partnerships, including peer-reviewed publications and new nutraceutical offerings. Social media discussion focused on these corporate developments and their potential market impact.
YDES technical picture
The stock price showed strong short-term upward momentum, trading above its 10-day EMA and significantly above its 50-day SMA. However, the price remained below its 200-day SMA, indicating a long-term downtrend. Momentum indicators like RSI and MACD showed mixed signals, with RSI approaching overbought territory and MFI suggesting neutral to slightly negative volume pressure.
Fundamentals
YD Bio Ltd (YDES) demonstrated significant year-over-year quarterly revenue growth and a positive trailing twelve months profit margin. However, the company has experienced historical net losses in prior years, though it maintains a strong cash position and robust short-term liquidity ratios.
Factors discussed — upside
- Year-over-year quarterly revenue growth of 314.9%
- Positive TTM Profit Margin of 24.7%
- Strong short-term liquidity with Current Ratio of 5.231
- Positive MACD indicating bullish momentum
- Significant recent price gains (+47.2% 7-day, +97.1% 91-day)
Factors discussed — risks
- Historical net losses in 2024 and 2025
- Price trading below the 200-day SMA, indicating a long-term downtrend
- MFI suggesting neutral to slightly negative volume-driven pressure
- RSI approaching overbought territory
- Revenue growth
- Profitability trends
- Technical indicators
- Product launches and partnerships
Summary updated .
YDES technical indicators
Common technical indicators for YDES, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 3.28 | Price above |
| 10-day exponential moving average | 3.80 | Price above |
| Relative strength index (14-day) | 62.15 | Neutral |
| MACD line (12/26/9) | 0.1083 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 2.63 – 4.92 | Price inside the bands |
Analyses
Recent YDES.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for YD Bio Ltd?
- The bull case for YD Bio Ltd centers on its significant year-over-year quarterly revenue growth and a positive trailing twelve months profit margin. The company also demonstrates strong short-term liquidity and has shown positive MACD indicators, suggesting bullish momentum.
- What are the risks for YD Bio Ltd?
- Risks for YD Bio Ltd include historical net losses in prior years and the stock trading below its 200-day simple moving average, indicating a long-term downtrend. Additionally, the Money Flow Index suggests neutral to slightly negative volume-driven pressure, and the Relative Strength Index is approaching overbought territory.
- Is YD Bio Ltd bullish or bearish?
- Recent AI analyses of YD Bio Ltd examined factors on both sides. Discussed upside: The bull case for YD Bio Ltd centers on its significant year-over-year quarterly revenue growth and a positive trailing twelve months profit margin. The company also demonstrates strong short-term liquidity and has shown positive MACD indicators, suggesting bullish momentum. Discussed risks: Risks for YD Bio Ltd include historical net losses in prior years and the stock trading below its 200-day simple moving average, indicating a long-term downtrend. Additionally, the Money Flow Index suggests neutral to slightly negative volume-driven pressure, and the Relative Strength Index is approaching overbought territory. These are descriptive observations, not a recommendation.
- What is the latest sentiment on YD Bio Ltd?
- News reports highlighted YD Bio Ltd's active engagement in research, product launches, and strategic partnerships, including peer-reviewed publications and new nutraceutical offerings. Social media discussion focused on these corporate developments and their potential market impact.
- How does Market Scanner analyse YD Bio Ltd?
- Every analysis of YD Bio Ltd runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh YDES.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.